Sugi Predict

Sugi Predict / Compounds / SCHEMBL1027809

SCHEMBL1027809

SCHEMBL1027809

CC(=O)Nc1cc(O)c(C(C)=O)cc1C

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 5/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ POLB P06746 4/20 0.46
▸ MAPT P10636 3/20 0.46
▸ ALDH1A1 P00352 3/20 0.44
▸ HPGD P15428 1/20 0.44
▸ KDM4E B2RXH2 4/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ ALOX15 P16050 1/20 0.44
▸ ESR1 P03372 1/20 0.43
▸ HTT P42858 4/20 0.43
▸ KMT2A Q03164 2/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ NCOA3 Q9Y6Q9 1/20 0.41
▸ LMNA P02545 4/20 0.41
▸ TSHR P16473 1/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ APOBEC3A P31941 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30007636 1.00 NPC1 (0.46) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL1028607 0.93 NPC1 (0.46) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL31398827 0.85 KDM4E (0.54) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL10821087 0.85 KDM4E (0.54) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL4259162 0.85 ALDH1A1 (0.47) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL21003306 0.84 SMN1; SMN2 (0.55) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL1025442 0.83 NPC1 (0.41) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL1025443 0.83 NPC1 (0.41) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL29174361 0.82 SMN1; SMN2 (0.42) NPC1RAB9APOLBMAPTALDH1A1
SCHEMBL3658766 0.80 CA1 (0.47) NPC1RAB9APOLBMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115215856-A Preparation method of PPAR delta agonist finadepa and intermediate thereof 沈阳药科大学 2022-10-21 — — CN claimed
CN-115215856-A Preparation method of PPAR delta agonist finadepa and intermediate thereof 沈阳药科大学 2022-10-21 — — CN disclosed
EP-3971176-A1 AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE Hinova Pharmaceuticals Inc. (CN) 2022-03-23 — — EP disclosed
WO-2020233512-A1 AROMATIC AMINE AR AND BET TARGETING PROTEIN DEGRADATION CHIMERA COMPOUND AND USE 成都海创药业有限公司 (CN) 2020-11-26 — — WO disclosed
US-20150299188-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2015-10-22 — — US disclosed
EP-2889291-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2015-07-01 — — EP disclosed
CN-104755465-A Heterocyclic compounds TAKEDA PHARMACEUTICAL 2015-07-01 — — CN disclosed
US-8513235-B2 Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-08-20 — — US disclosed
US-8263592-B2 Equilibrative nucleoside transporter ENT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 — — US disclosed
US-8263592-B2 Equilibrative nucleoside transporter ENT1 inhibitors JANSSEN PHARMACEUTICA NV (BE) 2012-09-11 — — US disclosed
EP-2486925-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION Mitsubishi Tanabe Pharma Corporation (JP) 2012-08-15 — — EP disclosed
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-08-02 — — US disclosed
CN-102056894-A Homocysteine synthase inhibitor MITSUBISHI TANABE PHARMA CORP 2011-05-11 — — CN disclosed
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR MITSUBISHI TANABE PHARMA CORPORATION (JP) 2011-02-10 — — US disclosed
EP-2275404-A1 HOMOCYSTEINE SYNTHASE INHIBITOR Mitsubishi Tanabe Pharma Corporation (JP) 2011-01-19 — — EP disclosed
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-11-04 — — US disclosed
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2010-11-04 — — US disclosed
WO-2009062990-A2 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2009-05-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196824-A1 THERAPEUTIC AGENT FOR CEREBRAL INFARCTION FABP7, TIMP3, MMP11 NPC1 450/4885RAB9A 1221/4885POLB 4635/4885
US-20110034440-A1 HOMOCYSTEINE SYNTHASE INHIBITOR BHMT, CBS, BHMT2 NPC1 1230/4885RAB9A 3994/4885POLB 1266/4885
US-20150299188-A1 HETEROCYCLIC COMPOUND PTGIS, LIPG, FEN1 NPC1 1105/4885RAB9A 3486/4885POLB 1221/4885
US-20100280025-A1 EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS SLC29A1, SLC29A2, SLC43A3 NPC1 90/4885RAB9A 999/4885POLB 1309/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.